in any other circumstances falling within Article 3(2) of the Prospectus Directive. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Bhatt RS, Berjis A, Konge JC, et al. State. Our team of . Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. | Learn more about Anne Koehler, PhD's . Sec Form D Bayer is committed to driving sustainable development and generating a positive impact with its businesses. By clicking on the I AGREE button, I certify that I am not located in the United States, Services & Downloads, AGM Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. local requirements that prohibit or restrict them from doing so. For the purposes of this provision, the expression an offer to the public in relation to any Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Bayer Global Contact Us - Nextpoint Questions about Nextpoint? These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Contact Us - Nextpoint While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. For more information, go to www.bayer.com. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Lists Featuring This Company Updates, Management & We provide these links merely for your convenience. Protection, Health and Distances, Work Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. States, Australia, Canada or Japan. Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. 2021 Feb;9(2):156-169. Safety, Science Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Compliance Policy, Bayer Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. I am currently pursuing a M.Sc. The Week's 10 Biggest Funding Rounds: Monogram And ShiftKey Land Huge In the United Kingdom the following materials are only directed at (i) investment professionals Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. In relation to each member state of the European Economic Area which has implemented the Directive The securities mentioned herein have not been, and will not be, registered under the Securities Act Use, Privacy & Solutions, Development NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Experience with Ph 1-3 immuno-oncology clinical trials preferred. Sanofi tops off venture arm, bringing fund to $750M | BioPharma Dive This announcement is an advertisement and does not, under any To learn more, visit nextpointtx.com. Responsible Lobbying, Climate, Environment and Kingdom, Contact Council, Stakeholder Fighting Counterfeit Drugs, New Safety I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Tony Arulanandam | Cytovia Therapeutics If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. to apply, The 5+ years experience leading cross-functional team operations including direct clinical trial management. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Trainee Program for Financial Management, Internal Slavery Act Statement, Position & New Talent, Bayer 04 NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. land, water and energy. & Socially Responsible Investing, Corporate NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Responsible Care, Bayer In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Both programs of the Boston-based company use the recently . We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. life. CAMBRIDGE, Mass. Interview, Check The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as offering or an invitation to the public in connection with any offer within the meaning of Statement, Cookie Arabia, South "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. There will be no public offer of the securities in any The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Career, Your NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Rankings, Vision & About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Degree in nursing, life sciences or a related discipline preferred. in the Pipeline, Trends in The Bayer brand stands for trust, reliability and quality throughout the world. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Natural Scientists, Global They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Counterfeits, Recognizing The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Member State, except that an offer to the public in such Relevant Member State of any securities may The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. the Bayer press portal. Products, Bayer Our scientific successes are intended to help improve peoples lives. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. & Stories, Working Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. The tender offer referenced herein is not being made, directly or We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. The following materials are not directed at or to be accessed by persons located in the United Protection, Environmental Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. the securities prospectus. in the United States absent registration or an applicable exemption from the registration access to the materials is prohibited or restricted. Life & Challenges, Reputation Bachelor of Science required, Masters of Science preferred. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). Bayer and the opportunities available. and Life in balance, Healthy Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Publications, Job Dr. Zang is professor of microbiology & immunology, of medicine, . Any person who wishes to view these materials must first satisfy themselves that they are Stock Market | sweetwaterreporter.com | Sweetwater Reporter Settings. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. materials or any of their contents. Your computer and mobile devices when you visit our Site. sufficient information on the terms of the offer and any securities to be offered so as to enable an Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). Stock Market | Finance Jan 10, 2023. www.precisiononcologynews.com . 2 Bhatt RS, Berjis A, Konge JC, et al. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Future Leadership Program - Engineers, Neither this announcement nor anything contained herein shall form the basis of, Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. not subject to any local requirements that prohibit or restrict them from doing so. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno ProBioGen Executes a Master Service Agreement with NextPoint Stockholders' Meeting, Notice Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. 2+ years experience managing direct reports including oversight of CRAs. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Stewardship, Pharmaceuticals Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Report, Quarterly Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. PDF Kurt focuses his practice on meeting the business and legal needs of The Bayer brand stands for trust, reliability and quality throughout the world. whatsoever in You can use our locations menu to find Bayer country websites and Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein.